⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Sironax Announces Option Exercise and Asset Purchase
globenewswire.com
NVS
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
globenewswire.com
GILD
NVS
BMY
CRSP
BIO
ADBT
BIIB
JNJ
REGN
AMGN
CELC
ALLO
MBIO
AUTL
Saudi Arabia Cell and Gene Therapy Manufacturing Market Poised for Growth Through 2035, Fueled by Advanced Technologies, Scalable Production and Rising End-User Demand
globenewswire.com
ICON
LAB
MEDP
NVS
TMO
World’s largest vision award goes to Botond Roska and José-Alain Sahel
globenewswire.com
NVS
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novartis AG (NVS) And Encourages Investors to Reach Out
accessnewswire.com
NVS
Digital Signature Market worth $66.26 billion by 2031 - Report by MarketsandMarkets™
prnewswire.com
DOCU
ADBE
SPNS
CHKP
MSFT
AMZN
NVDA
GOOG
IBM
INTC
AMD
QCOM
AMAT
ASML
MU
SMCI
CRWD
PANW
FTNT
DDOG
SNOW
ZS
PLTR
AI
UPST
COIN
RIOT
MARA
EXAS
REGN
GILD
BIIB
TEVA
MRNA
BMY
PFE
JNJ
ACGL
ALL
CB
AXS
PRU
MET
MS
GS
JPM
BAC
WFC
CMCSA
VZ
T
HPQ
DELL
HPE
CSCO
ORCL
SAP
CRM
NOW
MCHP
NXPI
ON
ADSK
CDNS
SNPS
VRSN
CYBR
OKTA
IDXX
ISRG
ROST
ULTA
TJX
MDT
ABBV
AMGN
LLY
NVS
AZN
SNY
BABA
JD
PDD
NTES
BILI
IQ
XPEV
NIO
LI
TSLA
RIVN
LCID
GM
F
STLA
VWAGY
TM
HMC
RBLX
GOOGL
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
globenewswire.com
NVS
CRIS
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
globenewswire.com
ALNY
IONS
SRPT
BIIB
NVS
AZN
NVO
SNY
ARWR
Single-Use Bioprocessing Connectors Market Set for Robust Growth Through 2033 as Biopharma Manufacturers Prioritize Flexible, Contamination-Reducing Systems
globenewswire.com
TMO
AVTR
AMGN
BMY
LLY
NVS
AZN
GILD
REGN
BIIB
VRTX
ISRG
MDLZ
DHR
AVB
ENGS
ENTG
Cell and Gene Therapies for Rare Disorders Poised for Breakthrough Growth Through 2036, Fueled by Innovation, Expanding Pipelines and Unmet Patient Needs
globenewswire.com
CSL
SANG
CAPR
SPRC
NVS